GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zafgen Inc (NAS:ZFGN) » Definitions » NonCurrent Deferred Liabilities

Zafgen (Zafgen) NonCurrent Deferred Liabilities : $0.00 Mil (As of Mar. 2020)


View and export this data going back to 2014. Start your Free Trial

What is Zafgen NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Zafgen's non-current deferred liabilities for the quarter that ended in Mar. 2020 was $0.00 Mil.

Zafgen NonCurrent Deferred Liabilities Historical Data

The historical data trend for Zafgen's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zafgen NonCurrent Deferred Liabilities Chart

Zafgen Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only - - - - -

Zafgen Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Zafgen NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Zafgen's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Zafgen (Zafgen) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3 Center Plaza, Suite 610, Boston, MA, USA, 02108
Zafgen Inc is a US-based biopharmaceutical company. It focuses on developing novel therapeutics that treat the underlying biological mechanisms through the methionine aminopeptidase 2, or MetAP2, pathway. The lead product candidate of the company is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection. The company operates in the business of developing novel therapeutics. The company primarily carries its business operations in the United States.